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We were very interested to read the  excellent 
article and commentary on arsenic and 
health, with respect to prenatal exposures, 
metabolic health, and underlying mecha-
nisms, by Ditzel et al. and Bailey et al. For 
many years there have been growing concerns 
as knowledge accumulates about the long-
term consequences of early-life influences on 
adult health (Fleming et al. 2015), including 
environmental programming resulting 
from prenatal exposure to arsenic (Farzan 
et al. 2013). These concerns rightly extend 
to metabolic consequences for the offspring 
(Ashley-Martin et al. 2015) and also encom-
pass epigenetic modifications as a result of 
developmental exposures to arsenic and other 
metals (Bailey and Fry 2014).
The elephant in the room, however, 
is the paucity of knowledge about what 
is happening to the human fetus early in 
gestation. A great deal of emphasis is placed 
on levels of toxicants in maternal urine or 
plasma, and on levels in the offspring at term 
(usually in cord blood), which is then often 
mislabeled as “fetal.” 
Last year we published a study of 
55 normally progressing, electively termi-
nated second-trimester human fetuses where 
changes in fetal hepatic cobalt levels were 
traced through vitamin B12 to changes in 
one-carbon metabolism and alterations in 
DNA methylation (Drake et al. 2015). We 
also characterized hepatic concentrations of 
essential and nonessential elements. Maternal 
smoking was validated by measuring circu-
lating fetal cotinine, and we were surprised 
to find no increase in the number of fetal 
livers with cadmium levels above limits of 
detection when the mother smoked (only 
5 of 55 fetuses had hepatic levels of cadmium 
above limits of detection, irrespective of 
smoke exposure) (Drake et al. 2015), despite 
a known increase in maternal cadmium 
levels with smoking (Sikorski et al. 1988). 
This clearly demonstrates the importance 
of studying fetal toxicant burden in our 
own species rather than simply making 
 assumptions from animal models. 
Relevant to Ditzel et al. and Bailey 
et al., we also published fetal hepatic arsenic 
concentrations and found levels above limits 
of detection in 39 of 55 fetuses, with a 
median arsenic concentration of 39.8 ng/g 
dry liver weight (Drake et al. 2015). As with 
cadmium, maternal smoking did not signifi-
cantly alter fetal hepatic levels of arsenic, 
and arsenic concentrations did not change 
between 11 and 21 weeks of gestation. 
These kinds of “real-life” human fetal data 
are essential to improve our understanding 
of the risks to the developing human, the 
points during gestation when those risks 
are most acute, and the key underlying 
mechanisms.
Editor’s note: In accordance with journal policy, 
Ditzel et al. and Fry et al. were asked whether they 
wanted to respond to this letter. Neither group 
chose to do so.
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